On the evening of April 15 as part of the InvestMaryland Challenge Award ceremony held at MICA in Baltimore, BHI presented three awards to local companies. Boss Medical LLC of Baltimore, ConverGene LLC of Gaithersburg, and Vasoptic Medical LLC of Columbia were selected for the awards based upon their high quality products under development, which have good possibility for securing federal funding with support and assistance. Each award – valued at $2,500 – consists of consulting services from BHI on Small Business Innovation Research (SBIR) or federal funding proposals. The SBIR program is designed to support small businesses in commercializing their technological research efforts.
Richard Bendis will speak at the Translational Research Forum during the 2013 BIO International Convention in Chicago. During the forum, speakers will address issues with current translational research models, explore new funding and collaboration opportunities, evaluate how to apply them to federal, academic, and private institutions. The session will take place Monday, April 22, from 4:35 p.m. – 5:25 p.m.
Location: Morgan, Lewis & Bockius Conference Center, 1111 Pennsylvania Ave., NW Washington, DC 20004-2541
National Brain Tumor Society is bringing together brain tumor researchers and industry executives to discuss how to move research from bench to bedside.
Biophrama executives and VC investors will share their criteria for investment and licensing of academic research.
Panelists include:
Lauren Abrey Global Development Team Lead, Genetech/Roche
Neil Exter Partner, Third Rock
Brian Gallagher Partner, SROne
Michael Glutch Managing Director, Medimmune Ventures
Perry Nisen Senior VP of Science Transactions, Pfizer
Nation Brain Tumor Society-funded researchers will present brain tumor drug candidates ready for early stage investment and/or licensing.
Friday, May 24 • 12:00 – 2:00 pm • Marriott Bethesda North Conference Center
Join the Montgomery County Department of Economic Development to celebrate small businesses. Attend the inaugural Small Business Awards program.
The award luncheon will provide countless opportunities to show your appreciation for the estimated 33,000 small businesses of Montgomery County—businesses that contribute directly to the strength of the area’s economy. Eight awards will be presented to eight distinct companies.
Cleave Biosciences has added $10 million in Series A financing from new investor New Enterprise Associates, bringing its Series A total to $54 million. In the fall of 2011, Cleave raised $44 million from US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors, Astellas Venture Management and Osage University Partners. The company is focused on cancer drug discovery and development.
Cleave is discovering novel drugs that affect protein degradation pathways. Cancer cells frequently make an excess of proteins and hence become dependent on protein degradation for their survival. By attacking key targets in these pathways, cancer cells fail to balance this excess protein synthesis with protein degradation and can no longer survive.
When he was young, Daniel J. Abdun-Nabi wasn’t all that interested in subjects like biology. He gravitated toward political science and the law in college, and worked for the federal Securities and Exchange Commission soon after graduating.
“I went out of my office and saw the Capitol. It was awe-inspiring,” Abdun-Nabi, 58, who grew up near Boston, said of working in Washington, D.C.
David Mott at New Enterprise Associates has spearheaded the development of an orphan drug accelerator that plans to hunt down the best in vivo-stage assets in academia, biopharma and the nonprofits, assemble them in a portfolio of rare disease therapies and mold them into pipeline programs that can be spun out into a slate of new biotech companies.
NEA’s high-profile biotech partner Mott–who helmed MedImmune until AstraZeneca ($AZN) came along and scooped it up for $15.6 billion–partnered with Pfizer Ventures and gained the support of Alexandria Real Estate Equities in piecing together the initial $16 million in startup funds for the newly coined Cambridge, MA-based Cydan.
GlaxoSmithKline, Britain’s biggest drugmaker, is placing a small but important bet on a new way of treating diseases by targeting electrical signals in the body.
The company said on Wednesday it would offer a $1 million prize to stimulate innovation in the field, as well as funding up to 40 researchers working in external laboratories.
The Global Virus Network plans to move its headquarters to the University of Maryland BioPark in Baltimore, officials announced Thursday.
Emerging pandemic viral threats and current viral killers are a worldwide problem. For this reason, the nonprofit GVN brings together the top medical virologists from more than 30 institutions in 21 countries, to promote international collaborative research, education and advocacy.
Pluristem Therapeutics (NASDSQ: PSTI) announced today that following favorable preclinical studies, United Therapeutics Corporation received approval to perform a human Phase I study in Australia using Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients diagnosed with Pulmonary Arterial Hypertension (PAH). On June 20, 2011 United Therapeutics and Pluristem entered into a licensing agreement pursuant to which United Therapeutics will develop, market and sell Pluristem’s PLX-PAD cells for PAH.
PAH is characterized by abnormally high blood pressure in the arteries of the lungs and leads to an increased workload on the right side of the heart.
Pieris AG and The Sanofi Group have jointly agreed to expand their ongoing discovery and development partnership to include a novel multispecific Anticalin® program. Under the existing framework of the 2010 agreement, the new program will entitle Pieris to an upfront payment from Sanofi and committed research funding as well as payments for the achievement of research, preclinical, regulatory and commercial milestones. Specific financial terms were not disclosed.
A test that detects human papillomavirus, a virus directly related to cervical cancer, has hit the market following approval by the China Food and Drug Administration.
“The careHPV test is faster, better and cheaper,” says Qiao Youlin, a respected epidemiologist, who headed a research project into the development of careHPV between 2003 and 2008. The research was assisted by the Bill & Melinda Gates Foundation, which contributed $13 million to the project.
Company: MedImmune Booth/Stand: 3344 Event: 2013 BIO International ConventionApr 22 – 25 2013 Chicago IL US
About MedImmune
MedImmune is the worldwide biologics research and development arm of AstraZeneca a global innovation-driven biopharmaceutical business that focuses on the discovery development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas including respiratory inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. MedImmune has approximately 2500 employees globally with its headquarters located in Gaithersburg Md. one of AstraZeneca’s three global R&D centers. For more information please visit www.medimmune.com.
When engineers at this university learned of a Baltimore neurosurgeon’s struggle to operate on sensitive parts of the brain, they designed a tiny robot to maneuver around more precisely than instruments held by a human hand during surgery — something Loh said never would have happened if the neurosurgeon and robotic engineers had not met. Now, one year into the partnership, the universities have launched a collaborative public health school, developed a joint biomedical informatics and bioimaging center and created a research and innovation program.
“When you have a formal structure for a partnership and encourage people to talk to each other, this is what the partnership between the universities is all about,” Loh said. “They have the problems; we have the solutions.”
The Tech Council of Maryland (TCM), Maryland’s largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, announced the finalists for its 25th Annual Dinner and Awards Celebration. Winners will be announced at the awards dinner on May 16 at the Bethesda North Marriott Hotel and Conference Center.
“This year’s finalists are a testament to the ingenuity and vibrancy of Maryland’s technology and life sciences community,” said Larry Letow, TCM’s chairman. “Their innovations advance the cause of a healthier, safer world while fostering job creation and prosperity here in Maryland. Simply put, Maryland’s tech and biotech companies are essential to our long-term economic growth. The TCM’s Awards Celebration is a great way to celebrate our members’ tremendous achievements to date and the bright future that lies ahead.”
The Tech Council of Maryland (TCM), Maryland’s largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, today commended state policy makers for advancing key priorities for the tech community during this year’s legislative session. The 2013 session concluded on Tuesday.
“Maryland’s policy makers delivered on our biggest priorities: stronger incentives for R&D and biotechnology, new incentives for cybersecurity investments, and corporate tax code certainty for employers,” said Larry Letow, TCM’s chairman. “We have many strong advocates in Annapolis who understand that Maryland’s technology and biotechnology companies are catalysts for innovation, job growth and prosperity.”
One of the world’s top physicians, Dr. Eric Topol, has a prescription that could improve your family’s health and make medical care cheaper. The cardiologist claims that the key is the smartphone. Topol has become the foremost expert in the exploding field of wireless medicine. Dr. Nancy Snyderman reports.
I launched a literary magazine in college. I actually thought that was a good idea. After a few too many 16-hour days of hustling ads and desperately scrounging for content, my grades tanked and my blood pressure skyrocketed. I learned that special kind of panic that comes from trying to execute on the inflated ambitions of a 20-year-old. The process consumed everything. (For the record, I regret nothing.)
My point is: The university setting is great for being entrepreneurial. But it takes organization and drive to hold it all together — something I realized I didn’t have. At least some of these young founders do.
Nominate your best startups to present to a select group of invitation-only investors and Global 1000 companies as part of the Virtual Startups Showcase (VSS) and the Exits Startups Showcase + Conference in San Francisco
NOMINATION DEADLINES
For University Startups: Friday, April 26, 2013
For Accelerator, Angel Investor and VC Portfolio Companies: Friday, June 14, 2013
The National Council on Entrepreneurial Tech Transfer (NCET2) asks universities, accelerators, Angel investors and VC’s to nominate their best startups and have them present to a select group of invitation-only investors and Global 1000 companies.
The need for innovation in healthcare has arguably never been greater. A range of factors, from aging world populations to rising standards of living in developing countries, are poised to drive long-run demand for innovative drugs, devices and medical technologies that can improve outcomes and reduce costs.
Ironically, however, funding for healthcare innovation remains in short supply. As industry participants are keenly aware, life science venture capital financing – which has played a critical role in helping translate research ideas into commercially useful medical technologies – is becoming increasingly scarce.
HHS Secretary Kathleen Sebelius joins Ellen Murray, the Assistant Secretary for Financial Resources (ASFR), and HHS agency leaders to announce the President’s HHS budget for Fiscal Year 2014.
The University of Maryland (UM) BioPark announced today that the Global Virus Network (GVN) is the Park’s newest tenant. The GVN is a non-profit organization comprised of the top medical virologist in more than 30 institutions spanning 21 nations – and growing. GVN’s mission is to combat emerging pandemic viral threats and current viral killers through international collaborative research, training the next generation of medical virologist, education and advocacy.
Said Jim Hughes, President, Research Park Corporation, University of Maryland Baltimore, “It’s exciting for the UM BioPark to include the prestigious Global Virus Network as one of our tenants. We are also pleased to be able to offer GVN continued close proximity to its Scientific Director, Co-Founder, and world-renowned virus researcher Dr. Robert Gallo from the UM School of Medicine, whose Institute of Human Virology is located conveniently just down the street from the GVN’s new BioPark headquarters.”
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Pictured: Rich Bendis, BHI; Arkesh Mehta, Chikujee Therapeutics; Stephen Yoder, Pieras AG; Rick Soni, Rexahn Pharmaceuticals
Growlers was “abuzz” on March 20 with a large and diverse gathering of biotech professionals attending the monthly BioBuzz networking event. BHI CEO Rich Bendis welcomed the crowd and talked about the latest happenings at BHI. According to Andrew Eckert, “We received a lot of positive feedback on the location and found a number of folks were interested in speaking to somebody from BHI. I’m pretty confident this was one of the largest, if not THE largest turnout ever for a BioBuzz event.”
BioBuzz is working to build a stronger community by bringing the biotech workforce out of the labs to culture relationships, instead of just cells.
On April 2, BHI invited a team of NIH Office of Technology Transfer interns working with BHI EIR Todd Chappell for a Social Meeting. Also in attendance were two guest speakers. Bart Kus, Senior Manager of Portfolio Management MedImmune, spoke about his career track from the lab into business development. Errol Levy, EU Diplomat (Research and Innovation Counsellor) for the European Commission talked about opportunities in Europe and the upcoming Destination Europe Conference on April 11 in DC. It was a great event for all who attended.
Maryland has invested $500,000 in Cytomedix Inc., a regenerative medicine company in Gaithersburg.
The investment was made through the state’s Maryland Venture Fund and InvestMaryland program. The state said the money is part of a $27.5 million fundraising round by Cytomedix (OTC: CMXI) that will result in the company adding 13 new employees to its current staff of 55.
Tom Sadowski, President and CEO, of the Economic Alliance of Greater Baltimore has been appointed to UMBC’s Public Policy External Advisory Board. Created in 2003, the External Advisory Board provides advice and guidance to UMBC’s Department of Public Policy and the Maryland Institute for Policy Analysis and Research (MIPAR). An important part of their mission is to bring the University’s public policy expertise to bear on the concerns of the communities they serve.
GlaxoSmithKline is trying to expand the market for its Benlysta drug beyond lupus by launching a major study of the medicine as a treatment for a serious blood vessel disorder.
GSK acquired full control of Benlysta when it bought Human Genome Sciences for $3 billion last year. Current sales of the drug are modest, at 70 million pounds ($106 million) in 2012, but GSK hopes it will become a major seller.
BioMed Realty Adds 1.6 Million Square Foot Portfolio & Expands University / Research Institution Segment to 18% of Annualized Base Rents
BioMed Realty Trust, Inc. (NYSE: BMR) announced today that it has entered into a definitive agreement to merge with Wexford Science & Technology, LLC, a subsidiary of Wexford Equities, LLC, furthering BioMed Realty’s position as the leading provider of real estate to the life science industry. Wexford Science & Technology is a private real estate investment and development company that owns and develops institutional quality life science real estate for academic and medical research organizations, and that boasts well-regarded skills for urban development and redevelopment of life science real estate. The aggregate consideration for Wexford Science & Technology is approximately $640 million, excluding transaction costs and subject to adjustment based on working capital levels and construction and development costs incurred prior to closing. Wexford Science & Technology will operate as a wholly owned subsidiary of BioMed Realty.
The Maryland Department of Business and Economic Development has named three finalists in three separate categories of the final round of the InvestMaryland Challenge. The winning companies, to be announced April 15, will receive $100,000 in top prizes and $125,000 in cash and in-kind awards as part of the Maryland Venture Fund’s first business competition.
InvestMaryland is a state venture capital initiative managed by DBED and the state-run Maryland Venture Fund. The initiative raised $84 million through a tax credit auction in 2012 to invest in startup companies.
AstraZeneca ‘s ( AZN ) worldwide biologics research and development (R&D) unit, MedImmune recently acquired AlphaCore Pharma, a biotechnology company based in Michigan. Financial terms of the deal were not disclosed by the companies.
We note that the acquisition of AlphaCore Pharma adds ACP-501 (a recombinant human lecithin-cholesterol acyltransferase/ LCAT enzyme) to AstraZeneca’s pipeline. The candidate is being developed for acute coronary syndromes (ACS) and other high-risk atherosclerosis conditions for the rapid removal of tissue cholesterol.
Johns Hopkins researcher Se-Jin Lee was named Wednesday as the 2013 recipient of the Ho-Am Prize in Medicine, which recognizes outstanding accomplishments in medical research that pave the way to conquering disease. It is awarded each year to an ethnic Korean and is sometimes referred to as “Korea’s Nobel.”
Lee is best known for his discovery of myostatin, a hormone that regulates muscle mass, and related work that lays the foundation for new therapies for conditions such as muscle wasting and muscular dystrophy.
Those who join MedImmune feel a sense of ownership about their future. They thrive with a recognized leader in the biotechnology industry and the wholly-owned subsidiary of AstraZeneca plc.
Here, you will join passionate professionals who advance science, technology and medicine to develop products designed to help people live better lives. You will excel in an environment characterized by respect, integrity and growth opportunities…that encourages both individual contribution and collaborative entrepreneurial thinking. Our products and/or product candidates are designed to address areas of need in infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. Explore a MedImmune career as we strive to better more lives, more often, around the world.
The Maryland House of Delegates has passed a measure to adjust how money from a state venture capital fund can be used to try to make it more effective.
The House voted 107-25 on Saturday for the bill. That sends it to the Senate to consider amendments delegates made to the measure.
WIScience Scholarship: The Premier Catalyst for Developing Women Leaders in Science
Are you nearing completion of your graduate degree or fellowship, and wondering how you’re going to transition into the healthcare industry? Do you get nervous thinking about how to identify the career in healthcare that fits you best? Do you wish you had a mentor to discuss these concerns with? If so, then you are the perfect candidate to apply for the WIScience Scholarship: The Premier Catalyst for Developing Women Leaders in Science offered by the Mid-Atlantic chapter of the Healthcare Businesswomen’s Association (HBA).
President Obama unveils a bold new research initiative designed to revolutionize our understanding of the human brain, and discusses the importance of investing in American innovation to create jobs and strengthen our economy. April 2, 2013.
Since the passage of the Jumpstart Our Business Startups (JOBS) Act (H.R. 3606) last year, the financial and medical press has been buzzing about the potential for crowdfunding to revolutionize fundraising for early-stage biotech companies. Even more recently, a portal that is exclusively dedicated to crowdfunding biotech and healthcare start-ups launched at medstartr.com. Although there may be reason for biotech entrepreneurs to be excited about crowdfunding, there are significant limitations and risks to this approach as well.
There’s an interesting trend I’ve noticed with at least one healthcare accelerator I have been tracking. The members of the startups for the most part have increasingly more industry experience and seem more adept at finding pain points and delivering a workable solution to members of the healthcare ecosystem. And if the successes of Blueprint Health’s latest graduating class are anything to go by, healthcare companies are getting increasingly receptive to working with startups that can help them address some of the demands of the Affordable Care Act and some of its impacts with more innovative solutions.
Seeking to maximize ongoing research, innovative ideas and revenue-generating opportunities, more schools are creating entrepreneur-in-residence programs — and letting the experts do the work.
With millions of dollars of research funding and teams of experts at their disposal, more universities are seeking ways to turn research breakthroughs into business opportunities.
DreamIt Health, a new Philadelphia-based, health-focused chapter of incubator DreamIt Ventures, has announced its first class of ten startups. Independence Blue Cross (IBC) and Penn Medicine are sponsoring the class and Venturef0rth is providing the working space for the companies. The new accelerator was launched in December 2012.
The startups will be provided with up to $50,000 in funding, office space, mentoring, and resources for developing and testing health-related products. The incubator will last four months, and companies will receive coaching from both entrepreneurs and health care executives. DreamIt Ventures has launched 80 companies over the past four years, including one health-related startup, 1DocWay. Supporting sponsors include global professional services company Towers Watson, and law firms Morgan Lewis, and Pepper Hamilton.
Among 400 applications from 22 countries, 13 early stage healthcare companies have been chosen for a three-year entrepreneurship class run by StartUp Health and GE, according to a statement from the companies. The class members will each be assigned a GE mentor who matches their business model and get access to the resources the Fortune 50 company can wield to help scale their consumer health innovations. That could include working with GE Healthymagination, GE Healthcare, GE Capital, or some of its business units, depending on the members’ specific needs.
Digital health incubator Rock Health released data today that shows an increase in funding for med-tech startups in the first quarter of 2013.
Thirty-seven health deals were valued at a total of $365 million, which is 35 percent higher than the first quarter of 2012, “suggesting that 2013 will be another record year for the digital health industry,” the blog post reads.
Philadelphia has reached a milestone in its efforts to be recognized as a healthcare and life sciences hub with the start of its first health IT accelerator.
DreamIt Health’s inaugural class includes 10 startups. The four-month program co-sponsored by Independence Blue Cross and Penn Medicine includes members seeking to develop tools for healthcare providers to speed up diagnoses and improve outcomes.
GlaxoSmithKline ( GSK ) recently announced that it has initiated a phase III study to evaluate the use of Benlysta (belimumab) in patients suffering from anti-neutrophil cytoplasmic antibodies (ANCA) positive vasculitis.
The multi-centre, randomized, double-blind phase III study will assess the efficacy and safety profile of Benlysta in combination with azathioprine as a maintenance therapy in ANCA positive vasculitis patients.
A big-data revolution is under way in health care. Start with the vastly increased supply of information. Over the last decade, pharmaceutical companies have been aggregating years of research and development data into medical databases, while payors and providers have digitized their patient records. Meanwhile, the US federal government and other public stakeholders have been opening their vast stores of health-care knowledge, including data from clinical trials and information on patients covered under public insurance programs. In parallel, recent technical advances have made it easier to collect and analyze information from multiple sources—a major benefit in health care, since data for a single patient may come from various payors, hospitals, laboratories, and physician offices.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the launch of its Commercial Relevance Program (CRP). BHI’s CRP is designed to help life science companies navigate the complicated process of preparing applications for federal funding, inclusive of Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR), and other federal government awards.
“The federal grant application process can be very complex. Based on 2012 data released by the National Institutes of Health (NIH), Maryland ranks 32nd out of 50 states with regard to SBIR award success rates. We would like to improve on this – and are confident that the CRP will help companies be more successful with their submissions,” said Ethan Byler, Director, Innovation Programs, BioHealth Innovation, Inc.
“At the end of the day, it’s about helping Central Maryland companies to get the best results possible as they seek out federal grant awards as a means of non-dilutive funding,” he added.
The CRP incorporates a pre-proposal review by knowledgeable BHI staff and advisors prior to a life science company’s submission of a full proposal. Through this review process, applicants will receive a set of recommendations and tips for troubleshooting their proposal for federal funding.
Interested life science companies in Central Maryland should contact BHI today for more information. The following federal agency SBIR/STTR deadlines are fast approaching:
About BioHealth Innovation, Inc. BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.
Congratulations to Elaine Amir! Elaine, executive director of the Montgomery County Campus of Johns Hopkins University, was named to The Daily Record’s 2013 list of Maryland’s Top 100 Women.
The announcement brought kudos from JHU interim provost Jonathan Bagger.
BioMed Realty Adds 1.6 Million Square Foot Portfolio & Expands University / Research Institution Segment to 18% of Annualized Base Rents
BioMed Realty Trust, Inc. (NYSE: BMR) announced today that it has entered into a definitive agreement to merge with Wexford Science & Technology, LLC, a subsidiary of Wexford Equities, LLC, furthering BioMed Realty’s position as the leading provider of real estate to the life science industry. Wexford Science & Technology is a private real estate investment and development company that owns and develops institutional quality life science real estate for academic and medical research organizations, and that boasts well-regarded skills for urban development and redevelopment of life science real estate. The aggregate consideration for Wexford Science & Technology is approximately $640 million, excluding transaction costs and subject to adjustment based on working capital levels and construction and development costs incurred prior to closing. Wexford Science & Technology will operate as a wholly owned subsidiary of BioMed Realty.
The Maryland Venture Fund has awarded $300,000 to Adlyfe, a Rockville diagnostic test developer, as part of the state’s InvestMaryland program.
Adlyfe, which is developing an early detection test for Alzheimer’s disease, is also receiving a $200,000 grant from the Maryland Biotechnology Center.
Emergent BioSolutions, Inc., a global specialty pharmaceutical company, is generating fresh ideas from Michigan State University students at its Lansing location to improve operations.
Emergent BioSolutions, the Roscommon-based Lear Corp., the Saginaw-based Mistequay Group, Ltd. and approximately five other companies hosted more than 20 undergraduate and graduate business and engineering students on various projects. The initiative is the brainchild of Bill Demmer, the CEO of the Lansing-based Demmer Corp., who donated $5 million to the university to create the Marnie Demmer Center for Business Transformation in late 2011, MLive.com reports.
Sure, New Enterprise Associates is much, much bigger than most venture capital firms. And not all of their deals fall neatly into what we think of as traditional Series A-B-C venture.
NEA invests in private hospital systems in China. It does the occasional PIPE deal. It does big-ticket “growth” fundings that look a whole hell of a lot like private equity.
But NEA is definitely not a private equity firm, as it is here described in The Wall Street Journal.
Two announcements on Monday and Thursday of last week signaled a fundamental strategic and physical shift for biopharma giant AstraZeneca, including the establishment of a new corporate headquarters in a new UK location; the shift of small molecule and biologics R&D to three strategic centers around the world; and an eventual overall headcount reduction of 5,050 between now and the end of 2016.
On Monday, March 18, the company announced its intent to focus the R&D in three places, and to fully implement these plans by 2016:
As the CEO of Pulse8, John Criswell works with health insurance exchanges and long-term care facilities on big data and analytics, which gives him a purview into the back-end integration required for states and the federal government to setup HIXs. Yet, he’s optimistic that the gvoernment will meet the October 1, 2013 deadline.
Government Health IT Editor Tom Sullivan spoke with Criswell about the complexity of standing up HIXs, how the exchanges might fare come October, and the overarching opportunities that both HIX and health information exchanges will create as they amass mammoth data sets.
Monday, April 15th 5:30 – 8:30 p.m. at MICA’s Brown Center
After months of submitting business plans, scoring applications, developing special awards and partnering with us, it’s time to celebrate entrepreneurship! Please join us April 15th at Maryland Institute College of Art’s Brown Center as we announce the top three $100K winners.
Tech entrepreneurs will soon find a new home at Innovation Crossroads, the Eastern Shore’s first, full-service business incubator.
Gov. Martin O’Malley and the department of public works recently approved $1.2 million in funding from the Maryland Department of Business and Economic Development for construction of the incubator, the Dorchester County Council announced on Tuesday.
Innovation Crossroads is the planned anchor tenant of the newly constructed Cambridge-based Regional Technology Park.
“Transformation” is the best description of what is happening in health care right now. We are seeing historic changes in how health care is administered in the United States—with increased focus on quality of care versus just paying for a service. We are seeing changes in how people can enroll in health insurance—with the upcoming establishment of a new market place that will help more people get insured in this country than ever before. And, we are seeing changes in how people understand and make decisions about their own health—with an increasing number of tools and services becoming available to help individuals access health information and manage their own personal health data.
The Congressional hearings debating the regulatory framework for mobile health devices and apps made me think about how we view mobile health apps and the criteria we use to determine what makes some better than others.
And as we all think in terms of the NCAA college basketball tournament around this time, I thought we would do a mini tournament using mobile health apps.
As we come to the close of Q1 of 2013, LSN has compiled some insight into three of the hottest subsectors being targeted by investors in the medical technology space. New technologies are surfacing that are changing treatment philosophies, and more importantly, medtech is attracting a whole new class of investors such as corporate venture from the consumer electronics, digital media, and telecom space. Here are the three trend areas that are changing the world from the medtech investor perspective:
This the title [paraphrased] of a keynote given last week by Jonathon Bush, the CEO of AthenaHealth, at the Xconomy Mobile Madness conference in Cambridge, Ma. What follows are my notes from the speech. The ideas are Jonathon’s. I really like what he’s saying and mostly agree, and he puts it very well.
AthenaHealth’s base business is medical practice billing in the cloud. This is an example of technology-enabled transformation of the health care business system, which we believe will be a big opportunity for entrepreneurs going forward. Founded in 1997, AthenaHealth is now a successful public company (ATHN).*
A week after the Congressional hearings discussed how the US Food and Drug Administration’s impending regulatory guidelines (expected by October) will impact mobile health apps, aspiring and current digital health entrepreneurs may be rethinking their path. In a report dubbed “FDA 101,” health startup accelerator Rock Health has compiled a handy report to help digital health entrepreneurs assess whether their mobile health apps would be classified as medical devices by the FDA and require 510(k) clearance.
Some of the pressure to clear the waters has come from technology developments that have simply outpaced the regulatory environment. Another is that provisions of health care reform call for making greater use ofremote monitoring, to reduce healthcare costs. Providers are pretty keen to reduce costs where they can as well. Remote monitoring would be particularly helpful when it comes to patients with chronic conditions, such as congestive heart failure or diabetes or both, so they can have shorter hospital stays and care managers can be alerted for any changes in their vital signs.
President Barack Obama’s top healthcare adviser acknowledged on Tuesday that costs could rise in the individual health insurance market, particularly for men and younger people, because of the landmark 2010 healthcare restructuring due to take effect next year.
U.S. Health and Human Services Secretary Kathleen Sebelius said definitive data on costs will not be available until later this year when private health plans become authorized to sell federally subsidized coverage on new state-based online marketplaces, known as exchanges.
Many of the changes in the healthcare industry outlined by the Affordable Care Act and HITECH Act call for shifting to healthcare IT for helping physician practices run more efficiently to helping guide clinical outcomes. But the shift from paper based to digital records isn’t just happening among providers. It is carrying over into other industries that healthcare intersects such as pharmaceuticals, medical devices and more robust collaborations with payers.
Andrew Khouri of Quaker Partners, who also mentors Blueprint Health accelerator companies, highlighted some needs in healthcare that are creating interesting investment opportunities and some investment trends at a recent event at the University City Science Center. Khouri acknowledged the “industry is in turmoil” because there’s uncertainty about how the changes will work in practice from the transformation of payment models to setting up health insurance exchanges. But there’s so much momentum to reduce costs and improve outcomes that there is a lot of opportunity.
The Series A crunch has left the realm of Bigfoot and Nessie and is entering the realm of truth, at least according to Fenwick & West.
The law firm released the results of its 2012 Seed Financing Survey today, which found that the number of startups obtaining Series A financing after a seed round declined significantly in 2012.
As expected, the third and final (for now, at least) congressional hearing focused on the FDA’s regulation of mobile medical apps was the only one that provided new information for those already well-versed in mobile health. While the past two days of testimonies likely helped members of Congress better understand the concerns of those working or lobbying for the healthcare and technology industries, those testimonies did not reveal anything new about what was actually going on at the FDA.
This morning the FDA’s Christy Foreman, who serves as the Director of the Office of Device Evaluation at the Center for Devices and Radiological Health, shared a number of insights about mobile medical app regulation that before today had not been revealed. Here are five things we learned from the FDA’s testimony during the congressional hearing today:
Why not explore what’s to gain from crowdfunding when there’s nothing to lose? MedStartr’s co-founder and CEO Alex Fair explains.
Alex Fair, Co-Founder & CEO of MedStartr Thinking about joining the crowd? We know, your mother probably told you not to get mixed up with the wrong kind. But according to MedStartr’s Alex Fair, there’s a lot right with the mob mentality growing among today’s entrepreneurs; crowd communities are creating equitable springboards for promising startups. That’s right, we’re talking about crowdfunding. After all, there is strength in numbers— especially from those that come with dollar signs.
No action is good action. At least for online investment platform the Funders Club that today received a ‘no-action letter’ from the SEC stating that it will not recommend enforcement action.
The letter is a green light for the FundersClub and validation that its investment model is legal. The news is significant for the venture capital and finance industries, as well as startups looking for more flexible methods of fundraising.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the launch of its Commercial Relevance Program (CRP). BHI’s CRP is designed to help life science companies navigate the complicated process of preparing applications for federal funding, inclusive of Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR), and other federal government awards.
“The federal grant application process can be very complex. Based on 2012 data released by the National Institutes of Health (NIH), Maryland ranks 32nd out of 50 states with regard to SBIR award success rates. We would like to improve on this – and are confident that the CRP will help companies be more successful with their submissions,” said Ethan Byler, Director, Innovation Programs, BioHealth Innovation, Inc.
“At the end of the day, it’s about helping Central Maryland companies to get the best results possible as they seek out federal grant awards as a means of non-dilutive funding,” he added.
The CRP incorporates a pre-proposal review by knowledgeable BHI staff and advisors prior to a life science company’s submission of a full proposal. Through this review process, applicants will receive a set of recommendations and tips for troubleshooting their proposal for federal funding.
Interested life science companies in Central Maryland should contact BHI today for more information. The following federal agency SBIR/STTR deadlines are fast approaching:
About BioHealth Innovation, Inc. BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.
MedImmune’s Gaithersburg headquarters will gain 300 new jobs under a broader U.S. consolidation by parent company AstraZeneca PLC, the companies announced Monday.
The move follows management changes at both companies. Pascal Soriot was named AstraZeneca CEO in August, and early this year carried out a leadership shuffle that included installing Bahija Jallal as MedImmune’s new chief. She replaces Peter Greenleaf, who is heading AZ’s Latin American unit.
Demonstrating its deep interest in the future of rare diseases, Pfizer ($PFE) has signed on to partner with Gaithersburg, MD-based GlycoMimetics on its lead drug program for sickle cell disease, promising up to $340 million in a broad array of milestones and an unspecified upfront payment. The partnership will bring in Pfizer on the development of GMI-1070, an inflammation inhibitor that researchers have been studying in a Phase II trial for the painful vaso-occlusive crises that threaten the organs of sickle cell patients.
In a demonstration of the booming field of genomic research, investors have pumped $21.3 million into a company that makes and manufactures genome-wide research tools and services.
OriGene Technologies said its Series C was led by Chinese venture firm Qiming Venture Partners and Kleiner Perkins Caufield Byers China, with participation from previous investor IDG-Accel, a China-focused private equity firm.
Montgomery County is implementing a Smart Growth Initiative to build on the area’s strengths in biotechnology and health care in a way that will create mixed-use neighborhoods and walkable new housing developments.
The three places where most of this new construction will occur are the Greater Seneca Science Corridor along Route 28, the White Oak Science Gateway west of Gaithersburg and the White Flint expansion along Rockville Pike. Each project possesses the core elements of walkability, rapid transit options and mixed-use development.
The outsourcing of information technology jobs being seen at Bethesda hotel giant Marriott International is not likely a harbinger of more to come, technology and business officials say.
Marriott executives said this week they are cutting “hundreds” of jobs and reorganizing the company’s information technology department in Bethesda in response to a more competitive global business environment. Layoffs are expected to start as early as next month.
Sequoia Holdings, Inc., a leading provider of software development solutions to the U.S. Intelligence Community, is teaming up with Washington DC area private equity and venture capital firms to launch an accelerator focusing on new cyber security and analytic startups. Based in Reston, VA, Sequoia Apps, LLC will concentrate on helping local entrepreneurs create and launch successful startups and connect them to DC area venture capital, private equity and angel investors for additional funding opportunities.
In addition to seed funding, mentoring and coaching, Sequoia Apps is designed to help capitalize on the successful past performance and unique skill sets of all IC focused developers and engineers and help build viable and disruptive commercial applications. “Sequoia Apps is a great example of how companies can leverage the successful past performance of their employees and connect them to the intellectual and financial scene of the DC startup community,” said T. Richard Stroupe, Jr. Sequoia Holdings co-founder. “For years, our development staff has designed and built world class applications for various IC customers, and now we would like to create a new disruptive platform to invest in those engineers in order to help them achieve similar success in emerging markets”.
In a move sure to inflame the libertarian blogosphere, a presidential ethics commission recommended today that researchers study the effects of anthrax vaccine on children.
The Presidential Commission for the Study of Bioethical Issues said researchers must first overcome numerous challenges before testing a pediatric version of the anthrax vaccine, intended to protect the American population from a potential bio-terrorist attack.
Startup Maryland (www.startupmd.org), a regional initiative of the national Startup America Partnership (www.s.co), today announced the Raise Your Game initiative to provide the Maryland entrepreneur community with a structured educational program designed to help startup CEOs and founders understand and employ the building blocks of strong startups and startup communities.
Development of the Raise Your Game program and curriculum was led by Startup Maryland Entrepreneur Champions Sam Polakoff, (president of TBB Global Logistics), Gregg Smith (CEO of Koolspan) and Startup Maryland co-chair Michael Binko (CEO of kloudtrack®). Beginning in July of 2013, Raise Your Game will consist of a 6 month educational “bootcamp” program emphasizing the critical components of building successful companies.
This week the US House of Representatives’ Energy and Commerce Committee is hosting a three-day series of hearings focused mostly on the FDA regulation of mobile medical apps. As of this writing two hearings have taken place, one held by the Communications and Technology subcommittee on Tuesday and another held by the Health subcommittee on Wednesday, but what could be the main event is set to take place early Thursday morning as representatives from ONC and FDA face questions from Congress.
Wednesday evening the testimonies for both the FDA’s Director of the Office of Device Evaluation Center for Devices and Radiological Health, Christy Foreman and the ONC’s National Coordinator Dr. Farzad Mostashari are now posted on the committee’s site. Neither includes any real surprises, but Foreman’s reiterates much of the FDA’s draft guidance and includes a note that any questions about the medical device tax should be directed at the IRS. The real discussion will come when Foreman and Mostashari answer the representatives questions after they read their prepared remarks.
Montgomery County has a plan to market itself as a business and tourist destination to a particularly captive audience — one traveling at 30,000 feet.
During April, air travelers on some 1,700 U.S. Airways flights, and select American Airlines flights (for business first class travelers only), will be targeted with videos promoting Montgomery County as a place to relocate a business, to live, work and play.
Cupid’s Cup Business & Innovation Showcase and Competition is where you’ll find the coolest innovations from the UMD campus and our region all under one roof. Pick the brains of entrepreneurs from all kinds of businesses. Take a break from the the dining halls and your usual lunch spots and visit the food trucks. Get to the competition early to score one of our limited-edition t-shirts. And definitely stay to watch our competitors duke it out in front of Under Armour Founder Kevin Plank.
Please join us to learn more about the uniqueness of Aeras: the product development partnership model, funding, center of excellence and CMO capabilities. Aeras, a not-for-profit, product development organization focused on developing safe, effective vaccines to prevent TB and ensuring they will be available and affordable for the populations that most need them.
A certain song has been running through my head the past few days. Lately, it strikes me as an anthem of sorts for biotech venture capital in 2013.
It’s Fleetwood Mac’s classic break-up song, “Go Your Own Way.”
Allow me to explain. Biotech venture capital has been going through a shakeout now for a couple years, which I’ve written about quite a bit. If you want to be charitable, there are maybe half as many venture firms investing in life sciences companies today as there were five to 10 years ago. There are maybe only a dozen firms left in the U.S. who can say with a straight face that they still are active investors in early-stage biotech startups. It may be harder now than it’s ever been to raise money for a new biotech idea.
Third Rock Ventures has spent the last six years betting big on early stage biotech investing when most other VC firms have been hunkering down or getting out of healthcare investing altogether. Now Third Rock has been rewarded with another $516 million to keep doing what it’s been doing.
The Boston and San Francisco-based firm, founded in 2007, said today it has raised its third fund, bringing its total assets under management to about $1.3 billion. The firm said this round was “oversubscribed” meaning that there wasn’t enough room to accommodate all the limited partners such as endowments and pensions who wanted a piece of the new fund.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Join us on March 20 at Growlers for another BioBuzz Happy Hour
Join our sponsors, BioHealth Innovation, Inc. (BHI) and the Johns Hopkins University Center for Biotechnology Education, along with many others from our local biotech industry at another exciting BioBuzz event on March 20 from 4:30 – 7 p.m. in Gaithersburg. This month, we’re having our event a week early to accommodate BioBuzzers with kids in Montgomery County Public School system who will be on spring break the next week. We’re also holding the March BioBuzz event at a new location, Growlers in Old Towne Gaithersburg. We’re excited to see all of you soon, so please register today!
Biopharmaceutical giant AstraZeneca announced today it plans to create a research and development center in Gaithersburg, adding 300 jobs at MedImmune’s current location.
MedImmune’s director of corporate public relations, Tracy Rossin, said no new buildings are planned at this point. Biotech company MedImmune, which is owned by AstraZeneca, currently houses AstraZeneca’s biologics programs, geared toward the creation of vaccines and medications.
Every week we give you a countdown of the top five to 10 companies or organizations from one of our Lists publishing in our Friday paper. This week I present to you the top five “Venture capital firms investing the most in Maryland companies,” ranked by total amount invested in Maryland companies in 2012. This information was provided to us by the folks at MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters.
Rockville biotech Sequella inc. is looking to raise at least $20 million to advance its lead antibiotic candidate through clinical trials in drug-resistant tuberculosis and the stomach bacteria H. pylori.
If there ever was a time for the company to hit the gas pedal, it’s now. The resurgence of tuberculosis, especially in populous nations such as India and Russia, has brought what was thought of as a 19th century disease back into the spotlight. And the rise of multiple-drug-resistant strains of TB has made that fear very real in the mind of the U.S. consumer.
People looking to start a small business in Montgomery County can have some of their questions answered at a series of seminars focusing on small business in Germantown.
Three seminars will be held between March, April and May by Score DC, a chapter of the U.S. Service Corps and Retired Executives, and will have mentors on hand to discuss successful business practices.
As our April 5, 2013 receipt date approaches and you prepare your grant submission, please remember to work to register in all the required systems (DUNS, SAM, grants.gov, eRA Commons) in advance. These must all be complete before you can submit your grant application.
Company registration at SBA’s SBIR.gov is NOT required for submissions at this time. Solicitations issued after 1/28/2013 (not due dates for solicitations already on street prior to that date) will have instructions on how to register at SBA.
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Request for Applications (RFAs):
RFA-OD-13-004: Lasker Clinical Research Scholars Program (Si2) This FOA solicits applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers.
RFA-RM-12-022: NIH Director’s Biomedical Research Workforce Innovation Award: Broadening Experiences The purpose of this FOA is to seek, identify and support bold and innovative approaches to broaden graduate and postdoctoral training, such that training programs reflect the range of career options that trainees (regardless of funding source) ultimately may pursue and that are required for a robust biomedical, behavioral, social and clinical research enterprise. Collaborations with non-academic partners are encouraged to ensure that experts from a broad spectrum of research and research-related careers contribute to coursework, rotations, internships or other forms of exposure. This program will establish a new paradigm for graduate and postdoctoral training; awardee institutions will work together to define needs and share best practices.
RFA-RM-13-001: Planning Grants for the NIH Building Infrastructure Leading to Diversity (BUILD) Initiative (P20) The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions with expertise and innovative strategies for developing research and mentoring opportunities for undergraduate students from backgrounds underrepresented in biomedical research to submit applications for 6 month planning grants for the NIH Building Infrastructure Leading to Diversity (BUILD) initiative. The BUILD initiative aims to increase the diversity of the NIH-funded workforce by supporting collaborative programs that include novel approaches for enhancing undergraduate education, training, and mentorship, as well as infrastructure support and faculty development to facilitate those approaches.
RFA-RM-13-002: Planning Grants for the NIH National Research Mentoring Network (NRMN) (P20) The purpose of this Funding Opportunity Announcement (FOA) is to encourage organizations with experience in the mentorship of individuals underrepresented in the biomedical research workforce to submit planning grant applications for the NIH National Research Mentoring Network (NRMN). The NRMN will establish a nationwide consortium to provide networking and mentorship experiences for individuals from backgrounds underrepresented in biomedical research from the undergraduate to junior faculty level.
Program Announcement (PA):
PAR-13-137: Bioengineering Research Grants (BRG) (R01) The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach that can increase our understanding of and solve problems in biological, clinical or translational science.
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Known for its ancient castles and seaside mosques, the Turkish city of Trabzon is looking to raise its profile on a new front—biotechnology.
For inspiration on expanding the Trapzon region’s high-tech and environmental-based industry, a foreign delegation arrived in Baltimore on Tuesday to meet with the Maryland Department of Business & Economic Development.
At its annual meeting on March 8, the Maryland Business Incubation Association (MBIA) approved applications for membership for two new full incubator programs and one new associate program: The Harford Business Innovation Center, Betamore, and The Charles County Innovation Center (planning underway)—bringing current membership to 23 business incubators and innovation centers.
MBIA member organizations offer direct support to nearly 450 entrepreneurial ventures throughout the State from a wide variety of sectors. They foster entrepreneurship and contribute substantially to the Maryland economy through the creation of thousands of jobs and the generation of significant tax revenues.
In laboratory studies, Johns Hopkins researchers say they have found that stem cells from a patient’s own fat may have the potential to deliver new treatments directly into the brain after the surgical removal of a glioblastoma, the most common and aggressive form of brain tumor.
The investigators say so-called mesenchymal stem cells (MSCs) have an unexplained ability to seek out damaged cells, such as those involved in cancer, and may provide clinicians a new tool for accessing difficult-to-reach parts of the brain where cancer cells can hide and proliferate anew. The researchers say harvesting MSCs from fat is less invasive and less expensive than getting them from bone marrow, a more commonly studied method.
Results of the Johns Hopkins proof-of-principle study are described online in the journal PLOS ONE.
Roughly three years after announcing that he was expanding his California bioscience incubator to San Antonio, InCube Labs founder Mir Imran may wish he had made the move even sooner.
InCube has found willing investors, as well as corporate and community support, in the nation’s seventh largest city. That has allowed the organization to adjust its expectations and strategies in a way that could prove to be hugely beneficial for the life sciences entity and for San Antonio long-term.
New Enterprise Associates, a venture capital firm that’s invested some $13 billion in up-and-coming companies, has launched a brand-new design mentorship program to fuel innovation in the design industry. Called NEA Studio, the 12-week program will challenge five designers at a time.
Why the focus on design? “When a consumer gets a product, it’s usually because of the design of it,” said Dayna Grayson, an NEA partner, to Fast Company. “I feel like, if you’re really going to design a product and make it inherent at a company, it has to start at a founder level. So if the designer wants to be the founder, why not?”
As part of the Wyle-led team, Lockheed Martin (NYSE: LMT) has been selected by NASA’s Johnson Space Center to provide biomedical, medical and health services in support of all human spaceflight programs. These services under the Human Health and Performance Contract (HHPC) monitor astronaut health and enable bioastronautics research that benefits life on Earth.
The potential contract value to Lockheed Martin is about $250 million over the expected 10-year life of the contract. Lockheed Martin is responsible for flight hardware development, facilitation of life sciences research conducted on the International Space Station (ISS), human factors engineering to optimize tools and experiments for astronauts in zero gravity, radiation analysis, space food development, flight/ground crew training, and life sciences data archival.
As advances in genomics, molecular analysis, and data processing have propelled disease research forward, scientists and drug developers still face a formidable challenge: recruiting patients for their studies.
Genetic Alliance, a nonprofit that advocates for people with rare genetic disorders, is launching a new site called Reg4All that aims to entice more patients into clinical trials and disease research by giving them unprecedented privacy controls and greater say in how their data is used for research.
After McKesson, Cerner, Allscripts, Greenway and athenahealth made news at HIMSS13 this past week with the launch of the CommonWell Health Alliance – putting aside their competitive instincts, for a moment, to pledge their common commitment to interoperability and data liquidity – Healthcare IT News spoke with McKesson CEO John Hammergren about the road ahead.
Joining Hammergren in the discussion were David McCallie, vice president, medical informatics at Cerner, and Arien Malec, vice president, data platform solutions for McKesson’s connectivity business, RelayHealth (and, in his former role at the Office of the National Coordinator for Health IT, the driving force behind the development of the Direct Project).
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
The Economic Alliance of Greater Baltimore (EAGB) and BioHealth Innovation (BHI) in collaboration with the Baltimore Business Journal are proud to announce the publication of the Central Maryland BioHealth Entrepreneur’s Resource and Financing Guide.
This Guide will be a compendium of resources to BioHealth innovators and entrepreneurs working to start and grow new companies in the region. A wealth of resources exists in Maryland to support emerging BioHealth companies, however, they are not always readily accessible or captured in one place. The Guide will compile information on financial resources, university facilities and programs, economic development programs, and existing federal laboratory facilities and programs and how to work with them.
Join us on March 20 at Growlers for another BioBuzz Happy Hour
Join our sponsors, BioHealth Innovation, Inc. (BHI) and the Johns Hopkins University Center for Biotechnology Education, along with many others from our local biotech industry at another exciting BioBuzz event on March 20 from 4:30 – 7 p.m. in Gaithersburg. This month, we’re having our event a week early to accommodate BioBuzzers with kids in Montgomery County Public School system who will be on spring break the next week. We’re also holding the March BioBuzz event at a new location, Growlers in Old Towne Gaithersburg. We’re excited to see all of you soon, so please register today!
Aronson’s Technology Industry Services Group is partnering with Rich Bendis and BioHealth Innovation (BHI) to help transform Central Maryland into a leading biohealth entrepreneurial and commercialization region.
“The central Maryland region is home to research organizations, government agencies, universities and companies with extensive biohealth experience and capabilities,” remarked Alan Langelli, Senior Manager in Aronson’s Technology Industry Services Group. He continued, “Aronson is very excited about the opportunity to partner with BHI and support its goal of helping Central Maryland become a leading biohealth entrepreneurial and commercialization region.”
BioHealth Innovation, Inc., (BHI) a non-profit organization which strives to facilitate the development of commercially viable health IT products and companies by connecting market relevant research assets to appropriate funding, management and markets, is seeking a Health Information Technology (IT) Entrepreneur-in-Residence.
POSITION DESCRIPTION – Health IT Entrepreneur-in-Residence The Health IT Entrepreneur-in-Residence (EIR) will lead in the evaluation of early-stage health IT technologies, advise BHI on opportunities for new ventures, and build a portfolio commercially relevant health IT opportunities. The Health IT EIR influences the BHI organization by managing and providing information, intelligence and insights that drive critical business decisions. The Health IT EIR will work with early stage companies to launch and validate those companies while providing recommendations and insights on the direction of potential technologies. The Health IT EIR has the potential to also serve in a co-management role in a health IT accelerator.
Personal Genome Diagnostics Inc. (PGDx), a pioneer in conducting patient-specific analyses aimed at identifying genomic alterations in tumors, today announced a number of developments that will support its expanding business. The company licensed exclusive rights to Digital Karyotyping (DK), an important genome-mapping technology developed by the company’s founders at Johns Hopkins University. PGDx also announced that it is expanding into new facilities and has made a number of key hires, including Genzyme Oncology executive Antony Newton as Chief Commercial Officer.
Johns Hopkins University generally does well on U.S. rankings of the top colleges.
But how does it stack up against institutions of higher learning from around the world? Not bad. It ranks No. 19 in the Times Higher Education World Reputation Rankings of the top 100 universities from around the globe. The University of Maryland, College Park also comes up on the list, at 95.
The University of Maryland, College Park has cracked the top 100 global reputation ranking by a publication based in the United Kingdom, The Washington Post reported.
Times Higher Education shows that UMd. is in a group ranked 91-100, in a class with Monash University in Australia, Lund in Sweden, Bristol in the U.K., the Free University of Berlin and Texas A&M. The rankings were based on surveys of academics around the world. Johns Hopkins, in Baltimore, ranked No. 19, the highest from the local region. Harvard University was ranked No. 1.
GlaxoSmithKline (GSK) has submitted its albiglutide once-weekly injection for type 2 diabetes to European regulators.
If approved the biologic treatment, which was submitted for US approval in January, will be marketed as Eperzan.
Albiglutide is, along with lupus treatment Benlysta and heart disease drug darapladib, one of a trio of drugs GSK has developed with Human Genome Sciences.
Montgomery County-based Novavax is a biopharmaceutical company creating nanoparticle vaccines targeting a wide array of infectious diseases. In this new video, CEO Stanley Erck speaks about the different processes Novavax scientists are working on, and the overall momentum of the company. Mr. Erck also highlights the company’s partnerships with Path, LG Life Sciences, GE Healthcare, and Cadila Pharmaceuticals. Novavax is excited by the promising new data from clinical trials with its RSV vaccine candidate and pandemic influenza vaccine candidate, and by the potential of its technology platform. From discovery to commercialization, Novavax is positioned to develop the vaccines for tomorrow.
A tax measure that would create a new, more lenient capital gains rate for tech investors and entrepreneurs cashing out their stock in the District is “going to be a focal point” for the Gray administration’s policy efforts this year, Mayor Vincent Gray told me in an interview Friday.
Gray, discussing his upcoming trip to the South by Southwest technology competition in Texas and his broader efforts to expand the District’s tech startup scene, acknowledged that resistance to the tax cut persists in the D.C. Council, which tabled the tax break last summer:
“I don’t get the sense that they’re any further along,” he said.
Nevro Corp., a medical device company focused on improving pain relief in patients suffering from debilitating chronic pain, today announced it has completed a $48 million Series C financing round. The round was led by new investor Novo Ventures, joined by New Enterprise Associates (NEA) and Covidien Ventures. Existing investors participating in this financing round included Accuitive Medical Ventures (AMV), Bay City Capital, Johnson & Johnson Development Corporation (JJDC), Mayo Clinic, MPM Capital, and Three Arch Partners.
“We are excited to welcome premier investors Novo Ventures, NEA, and Covidien Ventures who share Nevro’s vision to be a leader in neuromodulation through continuous innovation”
Personalized medicine — the ability to tailor therapies to patients’ individual genetic characteristics — has long been the holy grail of the life sciences industry. The effort has produced a string of recent successes, including a host of drugs targeted to people with specific genetic profiles, the European approval of the world’s first gene therapy treatment, and a much-heralded leukemia treatment pioneered at Children’s Hospital of Philadelphia (CHOP) that uses tweaked versions of patients’ own cells to eliminate their cancer. While these advances are certainly exciting for patients, they raise a host of ethical, legal and financial challenges that people working in the field will need to address before personalized medicine can become a thriving business.
The challenges are so great, contends Wharton health care management professor Ezekiel J. Emanuel, that claims of a renaissance in medicine brought on by individualized approaches often seem hyperbolic. “Before we buy into this, we need to remember that almost every evaluation of what drives health care costs up points to new technologies,” says Emanuel, who is also a professor of medical ethics and health policy at Penn’s Perelman School of Medicine. “We need to be skeptical. We need to see the data before people buy into the idea that personalized medicine is going to produce cost savings and be so much better for the system.”
She sent her first tweet just after noon, and already Kathleen Sebelius (@Sebelius) has 2,000-plus followers.
The secretary of U.S. Health and Human Services is the latest federal health official to join Twitter and follows in the footsteps of colleagues Dr. Tom Frieden (@DrFriedenCDC), the director of the U.S. Centers for Disease Control and Prevention, and Dr. Francis Collins (@NIHDirector), director of the National Institutes of Health.
Big news was made at HIMSS13 on Monday when, in an unprecedented collaboration, some health IT heavy-hitters joined forces in an effort to push the needle on interoperability.
In announcing the launch of the CommonWell Health Alliance, executives from Cerner, McKesson, Allscripts, athenahealth, Greenway and RelayHealth touted what they say is a first-of-its-kind organization: a collaboration of rival vendors, uniting to enable care integration and data liquidity.
A little more than a month ago, Naomi Fried, chief innovation officer at Boston Children’s Hospital, tweeted: that most healthcare mobile apps are built for consumers and focus on health and wellness, while only 20 percent are clinical apps. She wrote: “We need more #hospital apps.” Naturally, this caught our attention.
“There’s a huge opportunity for mobile apps in the hospital environment,” Fried told MobiHealthNews in an interview ahead of the annual Healthcare Information and Management Systems Society (HIMSS) conference. Fried will be receiving a HIT Men & Women Award at HIMSS in New Orleans this week for being an up-and-coming innovator.
In 2009, President Barack Obama selected the Republic of Turkey as a pivotal port of call in his first trip abroad as the new President of the United States. That symbolic visit led to the launch of an initiative to boost trade and investment ties between the two strategic allies under what was called a “model partnership,” culminating in a $ 17 billion mutual trade volume. Following in the footsteps of the President, US Senator John Kerry will also visit Turkey in his first international tour as the new American Secretary of State. These visits further underline the significance of American-Turkish relations for this administration. As the 16th strongest economy in the world, Turkey is not only an important geopolitical ally, but also an increasingly valuable commercial partner.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the formation of its Commercial Relevance Advisory Board (CRAB). Members of the CRAB represent diverse business and academic organizations from throughout the region, such as venture capital firm New Enterprise Associates, Ernst & Young, the Howard Hughes Medical Institute, the University of Maryland (UMD), Johns Hopkins University, and leading biotechnology companies.
The CRAB will assist BHI in evaluating market-relevant research and product development opportunities as well as help determine the commercial applicability of emerging entrepreneurs, companies and their science or technology. BHI will utilize feedback from CRAB members as part of its due diligence process for establishing formal client relationships and potentially future investments.
In partnership with BHI, the SBIR Resource Center(R) is offering a daylong seminar on How To Win SBIR Awards(SM) – at all federal agencies – with a primary emphasis on the National Institutes of Health (NIH). This event incorporates ALL of the necessary strategic planning, persuasive proposal writing, project planning/management and Federal project cost-accounting strategies to make your application successful.
The Tech Council of Maryland (TCM), Maryland’s largest technology trade association with more than 400 life science and technology members employing more than 200,000 in the region, will honor Dr. James Barrett, a general partner in venture capital firm New Enterprise Associates (NEA), with its third annual Lifetime Achievement Award. Barrett will be presented the award at TCM’s Lifetime Achievement Gala, which is taking place March 6 at the Bethesda North Marriott Hotel and Conference Center.
The TCM Lifetime Achievement Award is given each year to a local individual who has gone above and beyond to serve the community at large over the course of his or her career. Recipients display commitment and leadership both in the field and within their company, fostering new ideas and encouraging creativity. The recipient also demonstrates generosity and compassion, making sure their work benefits others.
The InvestMaryland Challenge has whittled down the 259 start-up companies that applied to the business competition to 33 semifinalists.
Only nine of those companies will move on to be finalists in the contest; three will win grand prizes of $100,000.
On March 5 the semifinalists will pitch their ideas to a panel of judges and complete a product demonstration. Grand prizes will be announced April 15.
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notice:
NOT-HL-13-167: Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Centers (CC) The National Heart, Lung, and Blood Institute intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for institutions to participate as Clinical Centers (CC) for the NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network, a new multi-center clinical trials network that will develop and test prevention or early treatment strategies for Acute Lung Injury. Read more.
NOT-OD-13-043: NIH Operation Plan in the Event of a Sequestration The NIH continues to operate under a Continuing Resolution as described in NOT-OD-13-002, and therefore all non-competing continuation awards are currently being funded at a level below that indicated on the most recent Notice of Award (generally up to 90% of the previously committed level). Final levels of FY 2013 funding may be reduced by a sequestration. Despite the potential for reduced funding, the NIH remains committed to our mission to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability. Read more.
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
The Entrepreneur-in-Residence (EIR) will lead in the evaluation of early-stage technologies, provide a strategic plan for start-up companies, advise BHI on opportunities for new ventures, and lead the commercial strategy for mature assets. The EIR influences the BHI organization by strategically managing and providing information, intelligence and insights that drive critical business decisions. The EIR will oversee primary and secondary research and will provide strategic recommendations and insights on the direction of potential assets.
Richard Bendis will speak at the Translational Research Forum during the 2013 BIO International Convention in Chicago. During the forum, speakers will address issues with current translational research models, explore new funding and collaboration opportunities, evaluate how to apply them to federal, academic, and private institutions. The session will take place Monday, April 22, from 4:35 p.m. – 5:25 p.m.
On a recent business trip to China, I was automatically assumed to be an interpreter or assistant because I was helping with communication on both sides. I had to assert myself and remind my colleagues that I, too, had original thoughts to contribute. This small example shines light on the issue of how Asian women are often perceived. We are seen as competent and hard-working, partly due to stereotypes, but not necessarily powerful or influential. In fact, projecting an image of power can invoke some resentment and cause discomfort. A man I once supervised admitted to me that he was not used to having a woman as manager. At least he was honest, which made it easier to work out the problem.
Johns Hopkins’ John Wong, Ph.D., has won a BioMaryland LIFE Award, and Ronald Berger, M.D., Ph.D., and Hien Nguyen, M.D., were awarded funds from the Abell Foundation, the researchers learned last week. Each of the winners will receive $50,000 to help develop their discoveries for clinical use.
The prizes were awarded as part of the annual Joint Meeting of the Johns Hopkins Alliance for Science and Technology Development and the University of Maryland, Baltimore Commercial Advisory Board on Feb. 19. The meeting was attended by more than 150 venture capitalists, seasoned biotech entrepreneurs and business development executives from the biopharma industry. Judging committees evaluated presentations from two dozen university researchers before selecting the winners. The aim of the awards is to speed the translation of promising research into commercial application.
New technology from the University of Maryland (UM) could potentially provide a five-minute diagnostic test and a vaccine for tough-to-treat Staphylococcus aureus infections, including the antibiotic-resistant MRSA, often called a “super bug,” says inventor Mark Shirtliff, PhD, an associate professor at the UM School of Dentistry in Baltimore.
Shirtliff is the winner of the 2013 BioMaryland LIFE (Leading Innovative Faculty Entrepreneurs) Prize for the most promising technology from the University as awarded by a judging panel at the annual joint meeting of the UM Baltimore Commercial Advisory Board and the Johns Hopkins University (JHU) Alliance for Science and Technology Development.
Venture investment in health care cratered in 2012. While others cut back, SR One charged ahead.
The venture arm of GlaxoSmithKline formed in 1985 and has steadily invested $30 million to $50 million annually. Seeing strong prospects at a time when many conventional venture firms had to sit it out, SR One invested more than $50 million last year, making eight new deals and eight follow-on investments, said Jens Eckstein, its president.
If you need an effective drug today for age-related macular degeneration, the leading cause of blindness in the elderly, you need to get an injection at the back of the eye.
Waltham, MA-based Kala Pharmaceuticals believes it may be able to get the drug where it needs to go, without sticking a needle in your eye.
In 2009, President Barack Obama selected the Republic of Turkey as a pivotal port of call in his first trip abroad as the new President of the United States. That symbolic visit led to the launch of an initiative to boost trade and investment ties between the two strategic allies under what was called a “model partnership,” culminating in a $ 17 billion mutual trade volume. Following in the footsteps of the President, US Senator John Kerry will also visit Turkey in his first international tour as the new American Secretary of State. These visits further underline the significance of American-Turkish relations for this administration. As the 16th strongest economy in the world, Turkey is not only an important geopolitical ally, but also an increasingly valuable commercial partner.
GlaxoSmithKline encountered some stiff industry headwinds when it pledged to open up its data vault to outside investigators. But as of today it has a high-profile convert on its side. The biopharma giant Roche ($RHHBY) has agreed to follow in GSK’s ($GSK) footsteps, saying that it will work with an independent group which will be charged with sorting out and approving requests for access to anonymized clinical trial data for all approved products. If regulators can’t provide the data, says Roche, then the company will make it available.
“We understand and support calls for our industry to be more transparent about clinical trial data with the aim of meeting the best interests of patients and medicine,” said Daniel O’Day, chief operating officer of Roche Pharma. “At the same time, we firmly believe that health authorities need to remain the gatekeeper for drug assessment and approval. We believe we have found a way in which patient data can be provided to third party researchers in a legitimate environment that ensures patient confidentiality and avoids the risk of publishing misleading results or giving rise to public health scares and consequences.”
Government contractors across the U.S. have found themselves in a holding pattern over the past few years, adapting to constant delays and waiting for economic uncertainty to be resolved. Between continuing resolutions, the debt ceiling crisis, and the threat of sequestration, government contracting companies have struggled to find new ways to be successful in the face of change.
According to a recent white paper by the Professional Services Council, “between fiscal years 2011 and 2012, federal spending on service contracts dropped more than $5 billion, which translates directly into the elimination of tens of thousands of contractor positions across the nation.” This, combined with a rise in the award of lowest-priced technically acceptable contracts, the delay in the award of new contacts and shorter term task orders under existing contract vehicles are all signs that a storm is brewing. Increased audits and investigations into contracting fraud waste and abuse, the increase in more regulations and compliance issues, and the Federal Strategic Sourcing initiative are clear evidence of this prevailing wind.
A little more than a year ago the American Heart Association launched an accelerator to fund biotechnolgy and medical device startups to fill a crucial gap in research funding caused by the increasing hesitance of investors to risk support on early-stage innovation. Now, it’s getting ready for a $2 million fundraising round to invest in two companies by the end of the year. It’s also working with sister organizations and mission-driven investment organizations to identify areas of common interest.
In a phone interview with MedCity News, Ross Tonkens, the director of the Science & Technology Accelerator, and Major Gifts Officer Mark Germano said they’re forming a group of donors who can provide expertise to screen applications. These donors have investment backgrounds steeped in biotechnology, drug development and medical devices. They also have expertise in legal issues, commercialization, IP, regulatory, clinical trial design and conduct issues. In a lot of cases, these are people who have had personal or close contact with people who have had cardiovascular disease or a stroke and want to see things move from the [lab] bench to bedside.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Psyadon Pharmaceuticals has spent nine months working to enroll the 18 patients it needs for its phase 3 clinical trial involving its treatment for Tourette syndrome.
The Germantown company’s candidate, ecopipam, also targets Lesch-Nyhan disease, a genetic disorder that affects as many as 1,000 Americans, disrupting their ability to walk and causing self-mutilation.
Although Psyadon usually is not directly involved in its clinical trials — it usually uses companies called contract research organizations, which conduct trials for drug makers — it often tracks disease-related patient advocacy groups and sometimes uses this information to raise awareness of the trial, said CEO Richard Chipkin.
The University of Maryland’s Maryland Industrial Partnerships (MIPS) program today announces it is awarding $4.7 million to Maryland university researchers to help 16 local companies develop technology products.
The projects, which team companies with universities across the state, include gene-silencing for cancer treatment, a new cardiovascular diagnostic device, advanced chemical detection, distributed heating and cooling, fertilizers and soil amendments made from both fish waste and other mixtures, agricultural stormwater treatment, an heirloom tomato juice production system, temperature-detecting gel, a drug to treat lung fibrosis, advanced oyster seeding system, electronic baseball home plate, mobile solar milk chiller, and both a vehicle and sensor technology for inspecting bridges.
The young Leiden-based biotech company Mimetas has closed an agreement with a regional development company from the state of Maryland, USA. Biohealth Innovation Inc., in which regional governments, universities and companies collaborate, will assist in setting up a US branch to find customers and business partners for Mimetas in the USA.
Richard Bendis will be a speaker at the South by Southwest (SXSW) Conference which takes place from March 8-17 in Austin, Texas. SXSW is a set of film, interactive, and music festivals which occur every year in March. Mr. Bendis will be speaking on March 9th at a session titled “Entrepreneurs in Residence: Not Just for VCs.” In his presentation, Richard will introduce the BioHealth Innovation, Inc. EIR program and speak about some of the commercialization challenges being addressed creatively by the biohealth community in Maryland.
In partnership with BHI, the SBIR Resource Center(R) is offering a daylong seminar on How To Win SBIR Awards(SM) – at all federal agencies – with a primary emphasis on the National Institutes of Health (NIH). This event incorporates ALL of the necessary strategic planning, persuasive proposal writing, project planning/management and Federal project cost-accounting strategies to make your application successful. Walk away with a deep understanding of what it takes to win and an ability to customize SBIR/STTR win strategies for specific projects. Get equipped to evoke positive responses in SBIR/STTR proposal evaluators (very different from all other programs).
WHEN: Tuesday, 5 March 2013, 8:30am – 6:00pm (45 min. lunch break)
WHERE: Rockville Economic Development, Inc.95 Monroe Street – Rockville, MD 20850 (short walk from Rockville Metro Sta.) 301-315-8096 (location phone)
REGISTRATION: or call 410-315-8101 OR email the SBIR Center; Class limited to 18-20 participants
TUITION: $325 ($375 after February 25) — satisfaction assured or tuition is returned
DISCOUNT: BioHealth Innovation may underwrite $175 of the tuition for select biohealth companies through its Commercial Relevance Program. To inquire about the discount, Contact Ethan Byler
Life sciences research is a strong economic driver, even if it leads to few patents
As the economy continues to flounder, many cities are looking for ways to replicate Silicon Valley’s financial success. When seeking to catch the magic of those biggest successes — Apple, Google and Facebook — the word “innovation” gets thrown around frequently. And as intellectual property is taking on a larger and larger role in how companies do business in the Bay Area, many have equated innovation with patents.
A recent Sun article about innovation in Baltimore and Maryland focused on just that. It lamented that the Baltimore metro area came in 116th out of 360 metro areas for the number of patent applications per capita, and that the number of patents granted to Baltimoreans remained flat over the past decade. The article seemed to suggest that this lack of intellectual property growth was at least partially responsible for Baltimore’s lack of job growth.
The Entrepreneur-in-Residence (EIR) will lead in the evaluation of early-stage technologies, provide a strategic plan for start-up companies, advise BHI on opportunities for new ventures, and lead the commercial strategy for mature assets. The EIR influences the BHI organization by strategically managing and providing information, intelligence and insights that drive critical business decisions. The EIR will oversee primary and secondary research and will provide strategic recommendations and insights on the direction of potential assets.
University of Maryland, College Park and two other East Coast schools will share $3.75 million from the National Science Foundation to develop a regional hub for turning university research into marketable products and services.
University of Maryland will be working with George Washington University and Virginia Tech to create an Innovation Corps for the mid-Atlantic region. The initiative will aim to draw out the best research ideas from students and faculty members and bring them to the commercial market.
Rare Disease Day, held each year on February 28, was established to raise awareness about the estimated 7,000 rare diseases that affect about 25 million Americans. To mark the occasion in 2013, the NIH will host a free, two-day public event beginning on this day to focus on rare diseases research and advocacy activities supported by several government agencies.
The National Center for Advancing Translational Sciences (NCATS) Office of Rare Diseases Research (ORDR) and the NIH Clinical Center are organizing and hosting the event. Others involved include the U.S. Food and Drug Administration and Agency for Healthcare Research Quality, and patient organizations, such as the Genetic Alliance and National Organization for Rare Disorders. Register and learn more at https://events-support.com/events/Rare_Disease_Day .
Johns Hopkins University Applied Physics Laboratory has won a potential 10-year, $4,904,853,263 U.S. Navy for research, development and engineering work throughout the Defense Department.
The contract includes a five-year option for review and approval by the assistant Navy secretary for research, development and acquisition and the assistant defense secretary for research and evaluation, the Defense Department said Feb. 15.
McLean-based Science Applications International Corp., which announced plans in August to split off part of its operations into a separate publicly traded company, has decided on a name for the new business.
The spinoff, which will focus on national security, health and engineering, will be called Leidos.
Leaders of several Richmond-area biotechnology-related companies said Thursday that they foresee personalized medicine as a major force driving the industry’s growth, but access to capital for small firms with good ideas remains a challenge.
“Life sciences is really the big, huge growth industry,” said Mike Grisham, the chief executive officer of GPB Scientific, a Richmond-based company focused on using microchip technology in health and life-science research.
Some of Silicon Valley’s most prominent billionaires are making a big push to guide the tech world’s entrepreneurs into biotech.
Backing the Breakthrough Prize in Life Sciences are Yuri Milner; Sergey Brin and Anne Wojcicki; and Mark Zuckerberg and Priscilla Chan.
Fittingly, they’re making the announcement at the University of California at San Francisco’s Genentech Hall, a building named after one of the Bay Area’s biotech standouts.
The National Science Foundation said today that it will fund a major expansion of its Innovation Corps program, an effort to teach NSF-funded university researchers how to build profitable startups around their technologies.
In its initial stages, the two-year-old “I-Corps” program has been flying researchers to Stanford University, the University of Michigan, and Georgia Tech for prototype versions of the “Lean Launchpad” course originally developed at Stanford by serial entrepreneur and startup guru Steve Blank. Now the program is spreading to nine more universities, which have been singled out for three-year grants totaling $11.2 million.
This chart shows the pharmaceutical drugs with the most patents still in force.
The drugs with the most active patents are COMBIVENT RESPIMAT, KALETRA, ADVAIR HFA,FLOVENT HFA, VIVITROL, THALOMID, VYVANSE, REVLIMID, VENTOLIN HFA, andCHILDREN’S ALLEGRA ALLERGY.
The “valley of death” is a common term in the startup world, referring to the difficulty of covering the negative cash flow in the early stages of a startup, before their new product or service is bringing in revenue from real customers. I often get asked about the real alternatives to bridge this valley, and there are some good ones I will outline here.
According to a Gompers and Lerner study, the challenge is very real, with 90% of new ventures that don’t attract investors failing within the first three years. The problem is that professional investors (Angels and Venture Capital) want a proven business model before they invest, ready to scale, rather than the more risky research and development efforts.
The Association of University Research Parks (AURP), the world’s leading network of university research, science and technology park professionals, invites you to share your knowledge, expertise and experience by presenting at the 2013 International Conference in Philadelphia, Pennsylvania. This year’s theme is Inventing the Future.
Proven engines for economic growth and development, university research parks influence their communities in significant ways. AURP’s 2013 annual conference, hosted by The University City Science Center, will feature experts who will examine university research park best practices and the strategies which will develop a knowledge-based economy by increasing ties between university, research parks, government, and industry partners.
Interesting approaches and creative solutions to challenges surrounding this topic are sought for presentations.
The health care industry is undergoing major surgery. At the center of these operations is Rock Health, a startup accelerator dedicated to the intersection of healthcare and technology. Today, at a demo event at the University of San Francisco, 14 startups presented their ideas on how to transform and improve healthcare in the U.S..
Dr. Aenor Sawyer, an associate clinical professor at UCSF, said during her opening remarks that these companies are changing “how we take care of patients and how patients take care of themselves.” Whether it is managing secondary care, untangling the confusing labyrinth of insurance, or encouraging healthy lifestyle habits, these startups are holding the scalpels.
San Francisco’s Rock Health startup accelerator held its fourth semi-annual Demo Day at UCSF’s Genentech Hall Wednesday afternoon. Investors and journalists heard pitches from 14 startups working to introduce new health-related services for consumers and new ways to improve the efficiency of the U.S. healthcare system.
On the consumer side, one intriguing presenter was Beam Technologies, which is building a toothbrush embedded with motion sensors to detect how long a person has been brushing. A Bluetooth radio sends the data to a smartphone app. (Perhaps it should have been called the Bluetoothbrush.)
Montgomery officials are under no illusions about the county’s image among the Washington region’s young: boring.
“We’re a little sleepy,” said County Council member Roger Berliner (D-Potomac-Bethesda). “We go to bed early.”
For all its prosperity and family-friendly suburban appeal, Montgomery is in the throes of a midlife crisis. That angst has led to a new item at the top of the public policy agenda: a yearning to be hip.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Montgomery officials are under no illusions about the county’s image among the Washington region’s young: boring.
“We’re a little sleepy,” said County Council member Roger Berliner (D-Potomac-Bethesda). “We go to bed early.”
For all its prosperity and family-friendly suburban appeal, Montgomery is in the throes of a midlife crisis. That angst has led to a new item at the top of the public policy agenda: a yearning to be hip.
Sen. Barbara Mikulski (D) dropped by Rockville on Monday for lunch with the Montgomery County Council, where much of the hour-long meeting focused on the looming federal government sequester.
Mikulski said she realized the effect across-the-board spending cuts and furloughs of federal workers could have on the county, home to 17 agencies, 32,000 employees and the many contracting firms that work with those agencies. There has been little recent movement on avoiding the sequester on Capitol Hill.
The Entrepreneur-in-Residence (EIR) will lead in the evaluation of early-stage technologies, provide a strategic plan for start-up companies, advise BHI on opportunities for new ventures, and lead the commercial strategy for mature assets. The EIR influences the BHI organization by strategically managing and providing information, intelligence and insights that drive critical business decisions. The EIR will oversee primary and secondary research and will provide strategic recommendations and insights on the direction of potential assets.
The Department of Health and Human Services SBIR/STTR grant solicitation aimed at supporting small business innovation research is now available.
Through the PHS 2013-02 SBIR/STTR Omnibus Solicitation, U.S. small businesses are encouraged to submit investigator-initiated SBIR/STTR grant applications in response to a variety of identified topics related to the National Institutes of Health, the Centers for Disease Control and Prevention, the Food and Drug Administration and the Administration for Children and Families.
The SBIR/STTR Reauthorization Act of 2011 and the recently released SBIR and STTR policy directives have brought about numerous – and often times, complicated – changes. In an effort to keep the small business research community aware of the impending modifications, the NIH has set up a new website providing a detailed overview of its implementation plan. In addition, HHS intends to revise or re-issue the Omnibus solicitation later this year. To stay informed, download a copy of the current solicitation and request to be updated as changes are made.
The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program has announced $10M in funding for up to 10 new awards in FY2013.
The Phase IIB Bridge Award is designed to support the next stage of development for promising NIH-funded SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, diagnostics and prognostics, or interventional devices.
In partnership with BHI, the SBIR Resource Center(R) is offering a daylong seminar on How To Win SBIR Awards(SM) – at all federal agencies – with a primary emphasis on the National Institutes of Health (NIH). This event incorporates ALL of the necessary strategic planning, persuasive proposal writing, project planning/management and Federal project cost-accounting strategies to make your application successful. Walk away with a deep understanding of what it takes to win and an ability to customize SBIR/STTR win strategies for specific projects. Get equipped to evoke positive responses in SBIR/STTR proposal evaluators (very different from all other programs).
WHEN: Tuesday, 5 March 2013, 8:30am – 6:00pm (45 min. lunch break)
WHERE: Rockville Economic Development, Inc.95 Monroe Street – Rockville, MD 20850 (short walk from Rockville Metro Sta.) 301-315-8096 (location phone)
REGISTRATION: or call 410-315-8101 OR email the SBIR Center; Class limited to 18-20 participants
TUITION: $325 ($375 after February 25) — satisfaction assured or tuition is returned
DISCOUNT: BioHealth Innovation may underwrite $175 of the tuition for select biohealth companies through its Commercial Relevance Program. To inquire about the discount, Contact Ethan Byler
Dominick Murray has been unanimously confirmed by the Senate Executive Nominations Committee to be the next head of the state’s economic development office.
Murray is scheduled to be sworn in to the role of secretary of the Maryland Department of Business and Economic Development by Gov. Martin O’Malley on Feb. 21.
United Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension. The FDA classified the resubmission as a complete, class 1 response to FDA’s October 23, 2012 complete response letter and the FDA set a user fee goal date of March 31, 2013.
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly’s drugs.
The companies did not disclose terms of the new collaboration, but described it as a “broad” partnership that will cover “all therapeutic areas.”
The Cambridge Innovation Center, a longtime fixture of the Boston-area startup scene, is expanding its entrepreneur-friendly office space business to new cities—just as it continues to build a larger footprint in its hometown.
The CIC, which rents office space and related services to more than 500 companies in seven floors of a building near MIT, has been advertising for a general manager at a new Baltimore location. And CEO Tim Rowe says that’s not the only place the CIC is eyeing for a possible expansion.
The Maryland Department of Business and Economic Development said 71 startups that entered its InvestMaryland Challenge have been selected from more than 250 applications to advance to the competition’s next round.
Eventually, three companies will win $100,000 and a chance to pitch their business to potential investors.The $100,000 prizes will be awarded in three categories: life sciences, information technology and general business.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will provide a corporate overview presentation at the Cowen and Company 33rd Annual Health Care Conference in Boston on Monday, March 4, 2013 at 3:30PM Eastern.
A webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under “Investors”.
On Friday, the Department of Defense announced that it has awarded The Johns Hopkins University Applied Physics Laboratory a five-year, sole source, cost-plus-fixed-fee, indefinite-delivery/indefinite-quantity task order contract to conduct research, development, engineering, and test and evaluation work for programs “throughout the Department of Defense.”
The contract envisions Hopkins scientists performing up to 11,964,743 staff-hours’ worth of research and development work through September 2017. Work would be performed in “core competency” areas such as “strategic systems test and evaluation; submarine security and survivability; space science and engineering; combat systems and guided missiles; theater air defense and power projection; and information technology (C4ISR/IO), simulation, modeling, and operations analysis.”
A piece in Forbes this week calls attention to a recent trend in technology commercialization at universities: the use of crowdfunding.
The article focused on a collaboration between the University of Utah’s Technology Commercialization Office and the crowdfunding site RocketHub, which resulted in the University Tech Vault, a portal specifically for projects that come out of the university.
As Valentine’s Day approaches the occasion begs the question: what does it take for two companies in the biopharmaceutical industry to merge? Of all the things that could come between them, how do a biotech startup and suitable partner find each other in this crazy, mixed up world?
Like any good marriage, the reasons that bring a couple together span of a good merger is more than meets the eye. The companies involved share similar goals and work hard to ensure the union endures. But there are all sorts of things That was the gist of an insightful panel discussion at the BIO CEO conference in New York. Among the panelists were: Michael Margolis, a managing director with ROTH Capital Partners, Effie Toshav, partner with Fenwick & West H.Thomas Watkins, former president and CEO of Human Genome Sciences until it was acquired by GlaxoSmithKline, Michael Gilman, a senior vice president at Biogen Idec and Corrine Epperly, the director of strategy, alliances and transactions at Bristol Myers-Squibb (NYSE: BMS)
For years, U.S. life-sciences startups have sought to avoid some of the problems in their industry–including a scarcity of investment funding and a sometimes-daunting regulatory process–by raising funding or commercializing overseas.
Nowadays, foreign organizations and governments are the ones making the overtures, hoping that American life-sciences companies can create jobs and stimulate the life-sciences industries in their countries.
The steady departure of pharmaceutical industry jobs in recent years has helped other states, but hurt the standing of the nation’s medicine chest. As more companies take root in far-flung locations, the New Jersey and New York City region has dropped significantly in the national ranking of life sciences markets, according to a recent report on commercial real estate.
Last year, the region slipped to seventh place among metropolitan life sciences clusters from second place in 2011, according to the latest annual report from Jones Lang LaSalle, the commercial real estate firm. The reasons cited for the slide: ongoing consolidation following big mergers and the simultaneous efforts among such cities as San Diego to offer competitive environments.
Innovate Health Tech NYC invites software and hardware developers and other innovators living or working in New York City to create new commercially viable technologies that solve urgent health care problems. Individuals, teams, and companies with 10 or fewer employes can compete, and will be required to demonstrate a functioning prototype of a pre-commercial technology in their submission. Technologies may include, but are not limited to, healthcare analytics tools, clinical workflow management tools, mobile health applications, and wireless health monitoring devices. Contestants are encouraged, but not required, to address healthcare priority areas identified by New York City.
PILOT Health Tech NYC is an exciting new program which provides funding of up to $100,000 each to 10 innovative pilot projects to take place in New York City. The program seeks to match early-stage healthcare technology companies (‘innovators’) with key NYC healthcare service organizations or individuals (‘hosts’), including hospitals, physician clinics, payors, pharma companies, and nursing associations. Each pilot project will be focused on addressing defined needs of the healthcare industry and testing a technology prototype in a healthcare setting for a period of approximately 3-6 months.
The Rice University Business Plan Competition is the world’s richest and largest graduate-level business plan competition. It is hosted and organized by the Rice Alliance for Technology and Entrepreneurship, Rice University’s nationally recognized entrepreneurship initiative, and the Jesse H. Jones Graduate School of Business, the #4 Best U.S. Graduate Entrepreneurship program per the Princeton Review.
In its 13th year, 42 teams from around the world will compete on campus April 11-13, 2013 for more than an expected $1 million + in cash and prizes in front of over 250 judges, primarily venture capitalists and other investors. More than 1200 teams applied to compete in 2012 and the competition was supported by more than 130 sponsors. More than 133 past competitors have successfully launched their business after competing at Rice, are still in business today, and have raised more than $480 million in funding.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the appointment of GenVec, Inc. President and Chief Executive Officer Cynthia L. Collins to its Board of Directors. BHI also announced that BHI Founding Board Member Jerry Parrott, formerly with Human Genome Sciences, has stepped down from his board seat but will continue to remain active on BHI’s Commercial Relevance Advisory Board.
“Cindy’s addition to the BHI Board of Directors provides us with access to and perspective from another talented biopharma leader from this region,” said Scott Carmer, BioHealth Innovation, Inc. Chairman of the Board and Executive Vice President of Commercial Operations at MedImmune. “Her tremendous depth and breadth of experience across the industry, particularly with regard to diagnostics as well as therapeutic areas ranging from antivirals to oncology, will be an asset to the companies we work with who are seeking to commercialize biohealth innovations.
Lets collaborate on building a vibrant biotech (or any other) community! Nice chestnut, but how does one design a community that functions across industries, geographies, support organizations, academic institutions and federal labs, each with very different missions and views of their (and others’) roles? How do you find a shared vision for these variant groups, one that drives growth for the greater region and doesn’t cause the players for fight over each opportunity as if it is the last scrap of possibility we’ll see? How do you prevent such a vision from becoming another dusty whitepaper, where behaviors weren’t aligned to make it happen? I had a chance to discuss how such a collaboration should be designed with Rich Bendis, President & CEO of BioHealth Innovation (BHI), an organization which spans from Rockville to Baltimore.
The Entrepreneur-in-Residence (EIR) will lead in the evaluation of early-stage technologies, provide a strategic plan for start-up companies, advise BHI on opportunities for new ventures, and lead the commercial strategy for mature assets. The EIR influences the BHI organization by strategically managing and providing information, intelligence and insights that drive critical business decisions. The EIR will oversee primary and secondary research and will provide strategic recommendations and insights on the direction of potential assets.
Whether you are a budding life science entrepreneur or potential investor, this event should be of interest to you. Multiple speakers explain how to acquire funding from Venture Capitalists and other investors.
AGENDA:
6:00 PM- 6:30 PM Registration and Networking and Life Sciences Speed Dating (Refreshments Served)
6:30 PM – 6:45 PM Dr. Jeffrey Hausfeld–Welcoming Remarks and Society of Physician Entrepreneurs Introduction
6:45 PM – 8:00 PM “Show Me the Money!” presentation followed by Q & A
In partnership with BHI, the SBIR Resource Center(R) is offering a daylong seminar on How To Win SBIR Awards(SM) – at all federal agencies – with a primary emphasis on the National Institutes of Health (NIH). This event incorporates ALL of the necessary strategic planning, persuasive proposal writing, project planning/management and Federal project cost-accounting strategies to make your application successful. Walk away with a deep understanding of what it takes to win and an ability to customize SBIR/STTR win strategies for specific projects. Get equipped to evoke positive responses in SBIR/STTR proposal evaluators (very different from all other programs).
WHEN: Tuesday, 5 March 2013, 8:30am – 6:00pm (45 min. lunch break)
WHERE: Rockville Economic Development, Inc.95 Monroe Street – Rockville, MD 20850 (short walk from Rockville Metro Sta.) 301-315-8096 (location phone)
REGISTRATION: or call 410-315-8101 OR email the SBIR Center; Class limited to 18-20 participants
TUITION: $325 ($375 after February 25) — satisfaction assured or tuition is returned
DISCOUNT: BioHealth Innovation may underwrite $175 of the tuition for select biohealth companies through its Commercial Relevance Program. To inquire about the discount, Contact Ethan Byler
In this newsletter we proudly present the new Chairman of the Advisory Board: Richard Bendis.
With his expertise on innovation strategy The Technopolicy Network intends to strengthen its position as the global leading network on Science Based Regional Development and Science Based Incubation. In his article he will give you several insights in the opportunities that lie ahead of us.
This is the time to pay tribute to the achievements of our founding Chairman, Prof. Roger Stough. With his advice and support Prof. Stough made The Technopolicy Network to what it now is. In his article he looks back on the growth of The Technopolicy Network over the past decade.
The next event in Tech Transfer Speaker Series will be taking place on February 13, 2013 in the William E. Hanna, Jr. Innovation Center (9700 Great Seneca Highway Rockville, Maryland 20850).
TEDCO has undergone a number of changes over the past two years. These changes have resulted in a variety of new programs and changes to old programs. The talk will provide an overview of TEDCO’s new programs, including its affinity funds, and where TEDCO is headed as a funding organization.
Speaker: Stephen Auvil is the senior vice president for technology transfer and commercialization at the Maryland Technology Development Corporation (TEDCO). In this role, he is responsible for overseeing TEDCO’s funding programs.
Vaxin Inc., a clinical stage vaccine development company today announced the appointment of David Brake Ph.D. to its Board of Directors.
“Vaxin has a long history of product development in animal health. It will be great to have someone with David’s expertise in this area joining our Board,” said David J. Drutz, MD, Vaxin’s Chairman. “Vaxin has significant ongoing collaborations with Drs. Henry Baker and Nancy Cox at Auburn University in the development of a vaccine to sterilize dogs and cats and with Dr. Haroldo Toro also at Auburn University in the development of influenza and other vaccines for poultry. We now have someone to help provide valuable product development and business insights on these initiatives.”
Patrick O’Shea, Vice President for Research at University of Maryland, urges Congress to protect research students and ensure america’s future by stoping the sequester.
The University of Maryland, College Park (UMCP) was recently named as the 5th “Best Value in Public Colleges” by Kiplinger, trailing only the College of William and Mary, the University of Florida, the University of Virginia and the University of North Carolina at Chapel Hill.
Maryland was ranked 5th for in-state students and 10th for out-of-state.
The annual Kiplinger study bases its ranking on a combination of financial factors, including total cost-per-year and cost after need-based aid for in-state students, total cost-per-year and cost after need-based aid for out-of-state students and average debt at graduation. Kiplinger also factors in the schools’ admission rates and four-year-graduation rates.
GlaxoSmithKline (GSK), the British pharmaceutical company, reported lackluster fourth quarter earnings for 2012 this morning, with a 3.5% drop in revenue. But the company’s performance would have been much worse if it hadn’t successfully avoided a looming threat that every brand-name pharmaceutical maker faces from time to time: the end of a patent on a blockbuster drug.
GSK’s Advair inhaler (called Seretide in most of Europe and India)—used to treat asthma and chronic obstructive pulmonary disease—lost its patent at the end of 2010. Ordinarily, a cheaper, generic version of a patented drug comes out shortly after the patent expires, and the generic quickly eats away at the marketshare and revenue of its branded progenitor. But Advair still brings $8 bln in sales to GSK, making it the third highest grossing drug worldwide. The only other off-patent pharmaceutical in the top ten is Lipitor, used for treating high cholesterol, which earned its maker, Pfizer, less than half as much in 2012 as it did in 2011, the year its patent expired (in spite of Pfizer’s unprecedented campaign to keep Lipitor a top-seller by strategically slashing prices).
Julie Lenzer Kirk, Executive Director of the Howard County Economic Development Authority’s Maryland Center for Entrepreneurship and Co-Chair of Startup Maryland, will brief White House officials during an event intended to celebrate entrepreneurship and the Startup America Partnership. The briefing, by invitation only, will be held at 3 p.m., February 5 at the White House.
The Startup Maryland team was invited to share how their efforts have developed over the past year, as well as highlight the group’s themes and areas of concentration for the future. As one of the most active state-based regions over the past year, Startup Maryland has attracted more than 500 startup participants in the eight months since officially launching. In addition to Kirk, other Maryland participants include Startup Maryland Co-Chair and CEO of kloudtrack®, Mike Binko; Brian Murphy, founder/CEO of Smith Island Baking Co.; David Troy, CEO of 410Labs, Inc; and Johnny Shockley, Cofounder of Hooper’s Island Oyster Aquaculture Co.
There’s a special place in NIH’s heart for SBIR research to develop drugs, medical devices and other products that require FDA approval. For these capital intensive products where time horizons for market entry are long, many NIH institutes offer extra millions and extra years of SBIR grant support after Phase II ends.
For most institutes, SBIR Phase IIB Competing Renewal grants are the vehicle for giving extra money. At NCI and NHLBI, Bridge grants do the same thing.
A University of Maryland, College Park fundraising campaign that began in 2006 has reached its goal of $1 billion.
It was the largest fundraising drive ever undertaken by a public institution in the Washington and Baltimore region and the largest campaign of any public university in Maryland.
The school said it raised $1.008 billion from nearly 130 million individuals, companies and foundations, including 125,000 alumni.
After its outstanding success in Boston in 2012, AdvaMed 2013: The MedTech Conference is back in our nation’s capital, Washington, DC. AdvaMed 2013 is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. This must-attend event for the MedTech industry will be held September 23 – 25 at the Walter E. Washington Convention Center. Please visit www.advamed2013.com for more information on the MedTech Conference.
We all know that venture capitalists help entrepreneurs create and grow great companies. Those great companies create jobs and improve our standard of living. Yet what many don’t realize is that the traditional venture industry is consolidating.
Washington area private firms, such as New Enterprise Associates, Grotech, New Atlantic Ventures and Novak Biddle, that raise money from third-party investors are becoming fewer and farther between, with just over 500 such firms in the U.S. last year. Yet, our country’s most promising start-ups continue to get funded in part because of the rise of corporate venture capital.
Startup Maryland (www.startupmd.org), a state-wide initiative FOR Entrepreneurs…BY Entrepreneurs, today announced a partnership with CoFoundersLab (www.cofounderslab.com) to provide the Maryland entrepreneur community with a free way to find a co-founder/business partner. To meet this need Startup Maryland and CoFoundersLab combined efforts and brands to develop a TeamFinder portal – which is also unveiled today as a new Resource at: http://startupmd.org/buildmyteam/
The branded TeamFinder portal is the first component of Startup Maryland’s Connection initiative. Connection joins Celebration, Coaching and Capital as four primary Areas of Concentration for Startup Maryland throughout 2013 and beyond. These four guiding initiatives were officially announced last week at a White House reception during which Startup Maryland highlighted past successes and future plans for Presidential advisors and officials from several government agencies.
US venture capital (VC) funding in the life sciences sector, which includes the Biotechnology and Medical Device industries, dropped 14 percent in dollars and 7 percent in deals during 2012 according to a new PwC US report, “Double-digit dip” that includes data from the MoneyTree™ Report from PricewaterhouseCoopers LLP and the National Venture Capital Association based on data provided by Thomson Reuters. Venture capitalists invested a total of $6.6 billion in 779 Life Sciences deals during the year, compared with $7.7 billion in 836 deals during 2011. The number of Life Sciences companies receiving VC funding for the first time reached the lowest level since 1995 with only 135 companies receiving funding in 2012.
Compared to the prior quarter, Life Sciences venture funding rose 11 percent in Q4 2012 to $1.9 billion. Deal volume also increased, rising 12 percent to 187 deals compared to the prior quarter.
Congressman Michael Honda (D., Calif.), who has been representing Silicon Valley in the U.S. House of Representatives for the past 12 years, recently submitted a bill asking for Congress to create and fund a new office at the U.S. Food and Drug Administration, which would be called the Office of Wireless Health.
The office would be tasked with regulating the growing number of mobile, wireless health gadgets and applications, which have been proliferating wildly since the start of the smartphone craze.
There are more market research reports, survey results and industry metrics related to mobile and digital health floating around these days than in years past: Our recently published State of the Industry Q4/2012 Year in Review report included a summary of 16 different metric-loaded reports that published during the last three months of the year alone. That means results from one or more digital health surveys published each week leading up to the end of 2012.
While far from perfect, these market numbers help shape our perception of what’s really going on in the market at large. Rightly or wrongly, even small surveys can have this effect.
Clinical stage biopharmaceutical company Catabasis Pharmaceuticicals Inc. has pulled in an $8.7 million round of funding, according to federal documents.
This is the not the first investment round for the Cambridge, Mass-based company which is focused on the development of treatments for metabolic and inflammatory diseases. In 2010, the company closed a $48 million Series A financing backed by SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures. In December 2011, the company received an $8 million Series A extension.
As hospitals work to boost their efficiency and the quality of care they deliver, many are finding they need new ways to go about finding and creating solutions to their post-Affordable Care Act challenges. They’re also looking for new revenue streams.
With that in mind, one California health system put up $40 million to seed an independent, for-profit company that will help commercialize ideas that come from physicians and staff members while also feeding them promising new technologies and concepts from the outside.
This infographic from DrugPatentWatch shows that Sanofi Aventis, Merck, and GlaxoSmithKline face the most patent expirations this year. Perhaps not surprisingly, GlaxoSmithKline and Sanofi Aventis are also among the firms with the most drug patents.
Blue Button Plus (Automated and Interoperable Blue Button) can provide a technology path for startups and innovators to build new products and services to help Americans with their health. But beyond, technology startups and small businesses have to think about practical matters like funding. What are ways that the federal government is trying to help health startups, particularly health tech startups, develop and commercialize businesses?
The Small Business Innovation Research (SBIR) program is a federally-funded program encourages domestic small businesses to engage in Federal Research/Research and Development (R/R&D) that has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore their technological potential and provides the incentive to profit from its commercialization. By including qualified small businesses in the nation’s R&D arena, high-tech innovation is stimulated and the United States gains entrepreneurial spirit as it meets its specific research and development needs.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In a move sure to inflame the libertarian blogosphere, a presidential ethics commission recommended today that researchers study the effects of anthrax vaccine on children.
Montgomery County has a plan to market itself as a business and tourist destination to a particularly captive audience — one traveling at 30,000 feet.
Please join us to learn more about the uniqueness of Aeras: the product development partnership model, funding, center of excellence and CMO capabilities. Aeras, a not-for-profit, product development organization focused on developing safe, effective vaccines to prevent TB and ensuring they will be available and affordable for the populations that most need them.
Join us on March 20 at Growlers for another BioBuzz Happy Hour
BioHealth Innovation, Inc., (BHI) a non-profit organization which strives to facilitate the development of commercially viable health IT products and companies by connecting market relevant research assets to appropriate funding, management and markets, is seeking a Health Information Technology (IT) Entrepreneur-in-Residence.
She sent her first tweet just after noon, and already Kathleen Sebelius (@Sebelius) has 2,000-plus followers.
ittle more than a month ago, Naomi Fried, chief innovation officer at Boston Children’s Hospital, tweeted: that most healthcare mobile apps are built for consumers and focus on health and wellness, while only 20 percent are clinical apps. She wrote: “We need more #hospital apps.” Naturally, this caught our attention.
In 2009, President Barack Obama selected the Republic of Turkey as a pivotal port of call in his first trip abroad as the new President of the United States. That symbolic visit led to the launch of an initiative to boost trade and investment ties between the two strategic allies under what was called a “model partnership,” culminating in a $ 17 billion mutual trade volume. Following in the footsteps of the President, US Senator John Kerry will also visit Turkey in his first international tour as the new American Secretary of State. These visits further underline the significance of American-Turkish relations for this administration. As the 16th strongest economy in the world, Turkey is not only an important geopolitical ally, but also an increasingly valuable commercial partner.
In partnership with BHI, the SBIR Resource Center(R) is offering a daylong seminar on How To Win SBIR Awards(SM) – at all federal agencies – with a primary emphasis on the National Institutes of Health (NIH). This event incorporates ALL of the necessary strategic planning, persuasive proposal writing, project planning/management and Federal project cost-accounting strategies to make your application successful.
The Entrepreneur-in-Residence (EIR) will lead in the evaluation of early-stage technologies, provide a strategic plan for start-up companies, advise BHI on opportunities for new ventures, and lead the commercial strategy for mature assets. The EIR influences the BHI organization by strategically managing and providing information, intelligence and insights that drive critical business decisions. The EIR will oversee primary and secondary research and will provide strategic recommendations and insights on the direction of potential assets.
On a recent business trip to China, I was automatically assumed to be an interpreter or assistant because I was helping with communication on both sides. I had to assert myself and remind my colleagues that I, too, had original thoughts to contribute. This small example shines light on the issue of how Asian women are often perceived. We are seen as competent and hard-working, partly due to stereotypes, but not necessarily powerful or influential. In fact, projecting an image of power can invoke some resentment and cause discomfort. A man I once supervised admitted to me that he was not used to having a woman as manager. At least he was honest, which made it easier to work out the problem.
The Entrepreneur-in-Residence (EIR) will lead in the evaluation of early-stage technologies, provide a strategic plan for start-up companies, advise BHI on opportunities for new ventures, and lead the commercial strategy for mature assets. The EIR influences the BHI organization by strategically managing and providing information, intelligence and insights that drive critical business decisions. The EIR will oversee primary and secondary research and will provide strategic recommendations and insights on the direction of potential assets.
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly’s drugs.
Whether you are a budding life science entrepreneur or potential investor, this event should be of interest to you. Multiple speakers explain how to acquire funding from Venture Capitalists and other investors.
The next event in Tech Transfer Speaker Series will be taking place on February 13, 2013 in the William E. Hanna, Jr. Innovation Center (9700 Great Seneca Highway Rockville, Maryland 20850).
